Genmab A/S (NASDAQ:GMAB) Earns Overweight Rating from Analysts at Wells Fargo & Company

Stock analysts at Wells Fargo & Company started coverage on shares of Genmab A/S (NASDAQ:GMAB) in a research report issued on Monday,Benzinga reports. The brokerage set an “overweight” rating and a $40.00 price target on the stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 36.64% from the stock’s current price.

A number of other brokerages have also commented on GMAB. HC Wainwright lifted their price target on shares of Genmab A/S from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Guggenheim lowered their target price on Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, February 23rd. Truist Financial reiterated a “buy” rating and issued a $48.00 price target (down from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. Wall Street Zen cut Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Finally, Morgan Stanley assumed coverage on Genmab A/S in a research report on Monday, February 16th. They set an “equal weight” rating and a $34.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $40.58.

Genmab A/S Stock Performance

NASDAQ GMAB opened at $29.28 on Monday. The firm’s fifty day moving average price is $31.91 and its two-hundred day moving average price is $30.29. The stock has a market cap of $18.81 billion, a PE ratio of 18.95, a PEG ratio of 1.21 and a beta of 0.94. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.01 and a current ratio of 2.02. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $35.43.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Tuesday, February 17th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. The business had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.06 billion. On average, equities analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Hedge funds have recently added to or reduced their stakes in the business. CIBC Private Wealth Group LLC lifted its stake in Genmab A/S by 291.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after buying an additional 616 shares during the period. Osaic Holdings Inc. grew its position in shares of Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after buying an additional 440 shares during the period. CWM LLC increased its stake in shares of Genmab A/S by 50.5% in the 2nd quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after acquiring an additional 603 shares in the last quarter. NewEdge Advisors LLC increased its stake in shares of Genmab A/S by 1,229.0% in the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after acquiring an additional 1,143 shares in the last quarter. Finally, Brown Brothers Harriman & Co. lifted its position in shares of Genmab A/S by 143.4% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after acquiring an additional 780 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.